# Registry Measuring Impact of RNA Expression Testing on Treatment Decisions in Early Stage Lung Cancer and Assessing the Disease-free Survival With Long-term Follow-up (ONC006)

> **NCT02121899** · — · TERMINATED · sponsor: **Myriad Genetic Laboratories, Inc.** · enrollment: 44 (actual)

## Conditions studied

- Lung Cancer
- NSCLC
- NSCLC Adenocarcinoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02121899
- **Lead sponsor:** Myriad Genetic Laboratories, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2015-04
- **Primary completion:** 2017-06-30
- **Final completion:** 2017-07-31
- **Target enrollment:** 44 (ACTUAL)
- **Why stopped:** company decision to terminate
- **Last updated:** 2017-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02121899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02121899, "Registry Measuring Impact of RNA Expression Testing on Treatment Decisions in Early Stage Lung Cancer and Assessing the Disease-free Survival With Long-term Follow-up (ONC006)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02121899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*